×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NYSE:NVTA

Invitae Stock Forecast, Price & News

$2.83
-0.14 (-4.71%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.79
$3.13
50-Day Range
$2.13
$5.96
52-Week Range
$2.08
$33.81
Volume
8.28 million shs
Average Volume
10.17 million shs
Market Capitalization
$648.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.42

Invitae MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
444.8% Upside
$15.42 Price Target
Short Interest
Bearish
21.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.15mentions of Invitae in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$303,038 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.86) to ($2.46) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.05 out of 5 stars

Medical Sector

427th out of 1,433 stocks

Medical Laboratories Industry

12th out of 32 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

Invitae logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

NVTA Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Invitae (NYSE:NVTA) Shares Down 6.8%
Invitae (NYSE:NVTA) Sees Strong Trading Volume
Brokerages Set Invitae Co. (NYSE:NVTA) Price Target at $15.42
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Invitae (NYSE:NVTA) Given New $6.00 Price Target at Benchmark
Why Invitae Stock Plummeted by 15% Today
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Company Calendar

Last Earnings
5/03/2022
Today
7/07/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$15.42
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+444.8%
Consensus Rating
Hold
Rating Score (0-4)
2.28571428571429
Research Coverage
7 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-148.62%
Pretax Margin
-107.46%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$13.16 per share

Miscellaneous

Free Float
224,933,000
Market Cap
$648.89 million
Optionable
Optionable
Beta
2.03














Invitae Frequently Asked Questions

Should I buy or sell Invitae stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Invitae stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View analyst ratings for Invitae
or view top-rated stocks.

What is Invitae's stock price forecast for 2022?

7 brokers have issued twelve-month price targets for Invitae's stock. Their NVTA stock forecasts range from $6.00 to $25.00. On average, they predict Invitae's stock price to reach $15.42 in the next twelve months. This suggests a possible upside of 444.8% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

How has Invitae's stock price performed in 2022?

Invitae's stock was trading at $15.27 at the beginning of the year. Since then, NVTA shares have decreased by 81.5% and is now trading at $2.83.
View the best growth stocks for 2022 here
.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Invitae
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) posted its quarterly earnings data on Tuesday, May, 3rd. The medical research company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by $0.01. The medical research company earned $123.70 million during the quarter, compared to analysts' expectations of $129.31 million. Invitae had a negative net margin of 148.62% and a negative trailing twelve-month return on equity of 24.48%. The business's revenue for the quarter was up 19.4% on a year-over-year basis. During the same period last year, the company posted ($0.63) earnings per share.
View Invitae's earnings history
.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $133.76 million-$139.57 million, compared to the consensus revenue estimate of $128.13 million.

Who are Invitae's key executives?

Invitae's management team includes the following people:
  • Dr. Sean Emerson George Ph.D., Co-Founder, Pres, CEO & Director (Age 48, Pay $500.15k)
  • Ms. Yafei Wen, Chief Financial Officer (Age 49, Pay $422.73k)
  • Mr. Kenneth D. Knight, Chief Operating Officer (Age 61, Pay $1M)
  • Mr. Thomas R. Brida, Gen. Counsel, Chief Compliance Officer & Sec. (Age 51, Pay $425k)
  • Dr. Robert L. Nussbaum, Chief Medical Officer (Age 72, Pay $391.35k) (LinkedIn Profile)
  • Ms. Shelly D. Guyer, Chief Sustainability Officer (Age 62, Pay $430.44k) (LinkedIn Profile)
  • Mr. Robert F. Werner, Chief Accounting Officer & Principal Accounting Officer (Age 49)
  • Mr. Karthik Suri, Chief Product & Technology Officer
  • Mr. Jackson J. Finks C.F.A., CFA, Director of Investor Relations & Strategic Fin.
  • Mr. Lee Bendekgey, Chief Policy Officer (Age 64)

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $2.83.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $648.89 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for Invitae is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.